Translational Research & Biosimilars

Reference Antibodies

Standardized therapeutic biosimilars for assay validation, comparative efficacy studies, and protocol reproducibility.

Reference antibodies (often formulated as research-grade biosimilars of established therapeutic drugs) are highly standardized immunoglobulins manufactured to provide an absolute baseline for experimental comparison.

Because their binding kinetics, specificity, and structural characteristics are thoroughly documented and internationally recognized, reference antibodies serve as critical positive controls in early-stage drug discovery, diagnostic assay development, and clinical research.

Ensuring Reproducibility

By establishing a standardized performance benchmark, reference antibodies allow researchers across different laboratories to validate new assay protocols and ensure direct data comparability.

1. Core Applications of Reference Antibodies

Integrating reference antibodies into your experimental design fulfills several critical quality control functions:

• Benchmarking New Therapeutics: Serving as the "gold standard" positive control to evaluate the binding affinity and functional efficacy of novel drug candidates.
• Assay Validation & Calibration: Providing a reliable standard to calibrate ELISA curves, optimize flow cytometry panels, and validate in vitro functional assays.
• Cross-Laboratory Comparability: Ensuring that data generated across multi-site studies or over long temporal periods remain standardized and reproducible.
• Pharmacokinetic (PK) Studies: Acting as calibrators or assay controls when developing anti-idiotypic antibodies to monitor therapeutic drug levels in patient serum.

2. Featured Reference Antibody Portfolio

Biorbyt offers a diverse portfolio of research-grade reference antibodies targeting major oncological, autoimmune, and inflammatory pathways. Explore our featured biosimilar tools below:

Adalimumab Biosimilar

Anti-TNFSF2 / TNFα Reference Antibody

TNF-α is a potent inflammatory cytokine. This reference antibody is vital for studying autoimmune inflammation, rheumatoid arthritis, and evaluating targeted apoptosis in specific cancer lines.

Mepolizumab Biosimilar

Anti-IL-5 Reference Antibody

IL-5 is a key cytokine regulating eosinophil activation. This antibody serves as a benchmark for researching severe eosinophilic asthma and pulmonary inflammatory responses.

Rituximab Biosimilar

Anti-CD20 Reference Antibody

CD20 regulates calcium influx on B-lymphocytes. This reference is essential for modeling B-cell depletion therapies in non-Hodgkin lymphoma and autoimmune diseases.

Cetuximab Biosimilar

Anti-ERBB1 / EGFR / HER1 Reference Antibody

EGFR drives cell growth and proliferation. This benchmark antibody is used extensively in oncology to evaluate inhibitors that block tumor progression and metastasis.

Alemtuzumab Biosimilar

Anti-CD52 Reference Antibody

CD52 is a mature lymphocyte antigen. This antibody is a foundational tool for studying targeted lympholysis in chronic lymphocytic leukemia (CLL) and multiple sclerosis models.

Tocilizumab Biosimilar

Anti-IL-6Rα / CD126 Reference Antibody

By preventing IL-6 from binding to its receptor, this reference antibody is critical for analyzing "cytokine storm" suppression and severe inflammatory disease pathways.

Gemtuzumab Biosimilar

Anti-Siglec-3 / CD33 Reference Antibody

CD33 is a primary myeloid cell surface receptor. This antibody serves as a benchmark for developing antibody-drug conjugates (ADCs) targeting acute myeloid leukemia (AML).

Need a Specific Reference Standard?

Biorbyt provides an extensive catalog of research-grade biosimilars and reference antibodies to support your drug discovery and assay validation pipelines.

Search All Reference Antibodies